MX2016007581A - Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos. - Google Patents
Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.Info
- Publication number
- MX2016007581A MX2016007581A MX2016007581A MX2016007581A MX2016007581A MX 2016007581 A MX2016007581 A MX 2016007581A MX 2016007581 A MX2016007581 A MX 2016007581A MX 2016007581 A MX2016007581 A MX 2016007581A MX 2016007581 A MX2016007581 A MX 2016007581A
- Authority
- MX
- Mexico
- Prior art keywords
- oxazepin
- methylpropanamide
- imidazo
- triazol
- isopropyl
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title abstract 3
- 229950001269 taselisib Drugs 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a polimorfos cristalinos de 2-(4-(2-(1-isopropil-3-metil-1H-1,2,4-triazol-5-il)-5,6-dihidrobe nzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1H-pirazol-1-il)-2-metilp ropanamida (GDC-0032, taselisib), a métodos de uso, y procesos para preparar los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916657P | 2013-12-16 | 2013-12-16 | |
| PCT/EP2014/077666 WO2015091305A1 (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007581A true MX2016007581A (es) | 2016-10-04 |
| MX356804B MX356804B (es) | 2018-06-13 |
Family
ID=52023532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007581A MX356804B (es) | 2013-12-16 | 2014-12-15 | Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9266903B2 (es) |
| EP (1) | EP3083640A1 (es) |
| JP (2) | JP6302089B2 (es) |
| KR (2) | KR101902664B1 (es) |
| CN (2) | CN105829323B (es) |
| AR (1) | AR098762A1 (es) |
| AU (3) | AU2014365079B2 (es) |
| BR (1) | BR112016009665A8 (es) |
| CA (1) | CA2927125A1 (es) |
| HK (1) | HK1223101A1 (es) |
| IL (2) | IL244915A0 (es) |
| MX (1) | MX356804B (es) |
| RU (2) | RU2018119749A (es) |
| SG (3) | SG10201705673QA (es) |
| TW (2) | TWI638818B (es) |
| WO (1) | WO2015091305A1 (es) |
| ZA (1) | ZA201602534B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160375033A1 (en) * | 2015-06-29 | 2016-12-29 | Genentech, Inc. | Methods of treatment with taselisib |
| EP3881833B1 (en) * | 2015-06-30 | 2023-11-01 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| EP3615541A1 (en) | 2017-04-28 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
| CN111448195A (zh) * | 2017-09-27 | 2020-07-24 | 费多拉制药公司 | 二氮杂二环辛烷衍生物的晶型及其生产方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20121025A1 (es) | 2009-09-28 | 2012-08-06 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la p13k |
| NZ702244A (en) * | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| AU2014230812B2 (en) * | 2013-03-13 | 2016-04-07 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
-
2014
- 2014-12-15 BR BR112016009665A patent/BR112016009665A8/pt not_active Application Discontinuation
- 2014-12-15 EP EP14811921.7A patent/EP3083640A1/en not_active Withdrawn
- 2014-12-15 RU RU2018119749A patent/RU2018119749A/ru unknown
- 2014-12-15 TW TW103143724A patent/TWI638818B/zh not_active IP Right Cessation
- 2014-12-15 SG SG10201705673QA patent/SG10201705673QA/en unknown
- 2014-12-15 WO PCT/EP2014/077666 patent/WO2015091305A1/en active Application Filing
- 2014-12-15 SG SG10201705669QA patent/SG10201705669QA/en unknown
- 2014-12-15 CA CA2927125A patent/CA2927125A1/en not_active Abandoned
- 2014-12-15 CN CN201480068672.4A patent/CN105829323B/zh active Active
- 2014-12-15 KR KR1020167015862A patent/KR101902664B1/ko active IP Right Grant
- 2014-12-15 CN CN201811256901.1A patent/CN109293674A/zh active Pending
- 2014-12-15 KR KR1020187023324A patent/KR20180093138A/ko not_active Application Discontinuation
- 2014-12-15 TW TW105143616A patent/TW201731852A/zh unknown
- 2014-12-15 AR ARP140104667A patent/AR098762A1/es unknown
- 2014-12-15 MX MX2016007581A patent/MX356804B/es active IP Right Grant
- 2014-12-15 US US14/570,019 patent/US9266903B2/en active Active
- 2014-12-15 SG SG11201604903VA patent/SG11201604903VA/en unknown
- 2014-12-15 RU RU2016127039A patent/RU2658009C2/ru not_active IP Right Cessation
- 2014-12-15 JP JP2016558275A patent/JP6302089B2/ja active Active
- 2014-12-15 AU AU2014365079A patent/AU2014365079B2/en not_active Ceased
-
2016
- 2016-01-08 US US14/991,658 patent/US9481690B2/en active Active
- 2016-04-05 IL IL244915A patent/IL244915A0/en unknown
- 2016-04-14 ZA ZA201602534A patent/ZA201602534B/en unknown
- 2016-09-29 HK HK16111381.6A patent/HK1223101A1/zh unknown
- 2016-11-14 IL IL248965A patent/IL248965A0/en unknown
-
2017
- 2017-06-06 AU AU2017203819A patent/AU2017203819B2/en not_active Ceased
- 2017-06-06 AU AU2017203817A patent/AU2017203817B2/en not_active Ceased
- 2017-12-20 JP JP2017244553A patent/JP2018080179A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3209653A4 (en) | Process for the preparation of (r,s)-nicotine | |
| IL235659A (en) | History 3, 4 - Dihydro-h2 - Pyrido [1, 2 - a] Pyrazine – 1, 6 - Transformed deion used to treat (among other things) Alzheimer's disease | |
| EP3016936A4 (en) | Process for preparing clomazone, novel form and use of the same | |
| IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
| IL239558A (en) | Process for Preparation of 1 - ([3,1] Dioxolane-4-Illmethyl) -1 H-Pyrazole-3-Illamine | |
| MX356804B (es) | Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos. | |
| EP3016935A4 (en) | Process for the preparation of intermediate of dolutegravir | |
| EP3118207A4 (en) | Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same | |
| EP2981518A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF FLUVOXAMINE MALEATE | |
| WO2013184570A3 (en) | Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | |
| WO2017046816A3 (en) | Process for the preparation of derivatives of benzodioxole | |
| MX2016005222A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| HK1203509A1 (en) | Improved process for the preparation of 2-substituted-2-(6- (substituted)-7-methylbenzo[d][1,3]dioxol-4-yl)acetic acid derivatives 2--2-(6-)-7-[d][13]-4-) | |
| RS61908B1 (sr) | Postupak za proizvodnju kondenzovanih imidazolo derivata | |
| IL236480B (en) | A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2 | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| EP3024807A4 (en) | Reactive distillation process for the preparation of 1, 1, 1, 2, 3, 3, 3-heptafluoro-2-bromopropane | |
| LV14779A (lv) | 4-Amino-2-(1,2,3-triazol-1-il)-hinazolīna atvasinājumi un to sintēzes paņēmiens | |
| CO6650412A2 (es) | Proceso para la preparación de 8-alcoxi[1.2.4]triazol[1.5-c]pirimidin-2-aminas substituidas -5 | |
| IN2013MU02612A (es) | ||
| LV14663A (lv) | Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm | |
| IN2014CH01257A (es) | ||
| AU2013904483A0 (en) | Process for the treatment of kaolin | |
| PL395184A1 (pl) | Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |